Clarity Medical (01406.HK) announced on November 27th that the group's revenue decreased from approximately 0.102 billion Hong Kong dollars for the six months ended on September 30, 2023, to approximately 87.2 million Hong Kong dollars for the mid-term period of 2024, a decrease of 14.2%. In order to do so, the group actively implemented cost reduction measures without compromising service quality. In particular, the adjusted net loss (i.e. the loss before the one-off non-recurring impairment loss on buildings, equipment, and the right-of-use assets) decreased from approximately 20 million Hong Kong dollars for the six months ended on September 30, 2023, to approximately 11.3 million Hong Kong dollars for the mid-term period of 2024, reflecting a decrease of approximately 43.5%. The loss per share attributable to owners of the company for the period was 3.5 Hong Kong cents.

The company is steadfastly committed to delivering high-quality healthcare services, which remains at the core of the company's operations. The company firmly believes that this commitment, coupled with the company's strategic adjustments, will drive sustainable growth and deliver long-term favorable returns to its esteemed shareholders. The group understands that the inflationary environment inevitably leads to increased operating expenses.

Nevertheless, the company remains dedicated to maintaining financial discipline and optimizing its cost structure. Through careful expense management and the implementation of efficiency-enhancing measures, the company's goal is to provide outstanding ophthalmology medical services to patients while ensuring sustainable development.